Healthcare / Medical Care FacilitiesTokyo
$685.00
-12.00 (-1.72%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $199.1M · quality 50.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.2B
P/E
28.4x
↑EV/EBITDA
12.8x
↑ROE
16.3%
↑Gross Margin
33.0%
↓Debt/Equity
1.67
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+41.2%
FCF CAGR
+15.5%
FCF margin
7.8%
FCF / Net income
1.96x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.44B · net income $254.9M · FCF $500.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.44B | $6.44B | $5.13B | $2.61B | $2.29B |
| Net Income | $254.9M | $254.9M | $-29.8M | $441.4M | $265.1M |
| EBITDA | $648.5M | $648.5M | $224.9M | $559.9M | $427.2M |
| EPS | — | — | -2.92 | 41.78 | 25.13 |
| Gross Margin | 33.0% | 33.0% | 35.8% | 55.5% | 62.5% |
| Operating Margin | 9.3% | 9.3% | 2.1% | 19.2% | 16.2% |
| Net Margin | 4.0% | 4.0% | -0.6% | 16.9% | 11.6% |
| Balance Sheet | |||||
| Debt/Equity | 1.67 | 1.67 | 1.98 | 0.30 | 0.28 |
| Current Ratio | 1.58 | 1.58 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $500.6M | $500.6M | $199.1M | $111.8M | $325.2M |
| Returns | |||||
| ROE | 16.3% | 16.3% | -2.3% | 39.6% | 40.5% |
| Valuation | |||||
| P/E | 28.40 | 28.40 | — | 19.10 | 41.74 |
| EV/EBITDA | 12.77 | 12.77 | 39.70 | 14.02 | 24.79 |
| P/B | 4.57 | 4.57 | 5.77 | 7.56 | 16.89 |
| Growth & Yield | |||||
| Revenue Growth | 25.3% | 25.3% | 96.8% | 14.0% | — |
| EPS Growth | — | — | -107.0% | 66.3% | — |
| Dividend Yield | 1.4% | 1.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-2.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.92 → n/d
Residual
-3.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.